Overview

NCI-MATCH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Objective

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.

Clinical Trial Categories

Oncology

Sponsor(s)

National Cancer Institute (NCI)

Contact

Research study staff: 425.688.5407

Complete the online contact information form

Learn More
Location

Overlake Medical Center
1035 116th Ave. NE 
Bellevue, WA 98004
Main: 425.688.5000

View all hospital services

View all hospital services

Make a gift

Make a gift

Need urgent care?

Need urgent care?